Summary
Murray Selkirk earned his PhD at the National Institute for Medical Research, Mill Hill, where he studied immunosuppression in murine trypanosomiasis with Bridget Ogilvie. He then joined the University of Washington, Seattle, working with Nina Agabian on antigenic variation in trypanosomes, and after a brief spell at the Naval Biosciences Laboratory in Oakland, joined Rick Maizels at Imperial College to work on parasitic nematodes. He was appointed to a Lectureship in the Department of Biochemistry in 1986, promoted to Professor in 2001, was Head of the Division of Cell & Molecular Biology from 2005-2008, Head of the Department of Life Sciences from 2011-2017, and is currently Emeritus Professor of Molecular Parasitology. His research has focused largely on gastrointestinal nematode parasites, aiming to understand how these pathogens effect long-term survival in mammalian hosts, with a particular focus on molecular mechanisms underlying regulation of the host immune system and resistance to immunity.
Publications
Journals
Brown A, Selkirk ME, Sarkies P, 2023, Identification of proteins that bind extracellular microRNAs secreted by the parasitic nematode Trichinella spiralis, Biology Open, Vol:12, ISSN:2046-6390
Pillay R, Mkhize-Kwitshana ZL, Horsnell WGC, et al., 2023, Excretory-secretory products from adult helminth Nippostrongylus brasiliensis have in vitro bactericidal activity., J Med Microbiol, Vol:72
Hagen J, Ghosh S, Sarkies P, et al., 2023, Gene editing in the nematode parasite Nippostrongylus brasiliensis using extracellular vesicles to deliver active Cas9/guide RNA complexes, Frontiers in Parasitology, Vol:2, ISSN:2813-2424, Pages:1-14
Nash B, Gregory WF, White RR, et al., 2023, Large-scale proteomic analysis of T. spiralis muscle-stage ESPs identifies a novel upstream motif for in silico prediction of secreted products, Frontiers in Parasitology, Vol:2, ISSN:2813-2424, Pages:1-13
Almeida-Santos J, Berkachy R, Tye CA, et al., 2022, Temporal profiling of CD4 T-cell activation and differentiation upon SARS-CoV-2 spike protein immunisation